Hospital Acquired Disease Testing Market

1. Global Hospital Acquired Disease Testing Market accounted for US$ 7.2 billion in 2020 and is estimated to be US$ 14.91 billion by 2030 and is anticipated to register a CAGR of 7.6%.Viral, bacterial, and fungal pathogens cause hospital-acquired infections (HIA). Nosocomial infection, also known as hospital acquired infection, is an illness that develops in a specific site, such as a hospital, due to the presence of toxins. During their hospital stays, patients with impaired immune systems are at a greater risk of contracting an infection. Healthcare workers, infected medical equipment, bed linens, and air droplets are all potential sources of infection. Infection can also come from the outside world, another infected patient, or employees infected with an unknown pathogen. Catheter-related bloodstream infection, surgical site infection, ventilator- associated pneumonia, and catheter-associated urinary tract infection are all examples of hospital-acquired illnesses. The report"Global Hospital Acquired Disease Testing Market, By Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others) and By Region (North America, Europe, Asia Pacific, Middle East, Latin America, and Africa) - Trends, Analysis and Forecast till 2029’’ Key Highlights: In December 2021,The healthians and QRX launch rapid PCR covid test with turnaround time of 30 minutes. Analyst View: The rise of hospital acquired diseases is fueled by poor infection control techniques and procedures at healthcare facilities, as well as filthy and non-sterile environmental surfaces, which is propelling the hospital acquired disease testing market forward. Furthermore, rising antibiotic resistance as a result of enhanced medical treatment leads to the development of hospital-acquired infections, which fuels market expansion. Furthermore, the market is being driven by the rising occurrence of nosocomial infections such as surgical wounds, urinary tract infections, and lower respiratory tract infections in intensive care units, orthopaedics, and acute surgical wards. Browse 60 market data tables* and 35 figures* through 140 slides and in-depth TOC on “Global Hospital Acquired Disease Testing Market, By Test Type (Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others) and By Region (North America, Europe, Asia Pacific, Middle East, Latin America, and Africa) - Trends, Analysis and Forecast till 2029” To know the upcoming trends and insights prevalent in this market, click the link below: https://www.prophecymarketinsights.com/market_insight/Global-Hospital-Acquired-Disease-Testing-98 Key Market Insights from the report: Global Hospital Acquired Disease Testing Market accounted for US$ 7.2 billion in 2020 and is estimated to be US$ 14.91 billion by 2030 and is anticipated to register a CAGR of 7.6%. Global Hospital Acquired Disease Testing market is segmented into test type and region. Based on Test Type, the Global Hospital Acquired Disease Testing Market is segmented into Urinary Tract Infection, Surgical Site Infection, Pneumonia, Blood Stream Infection, Methicillin-resistant Staphylococcus Aureus, and others. By Region, the Global Hospital Acquired Disease Testing Market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

2. Competitive Landscape & their strategies of Global Hospital Acquired Disease Testing Market: The key players in the global Hospital Acquired Disease Testing market includes Diatherix laboratories, Life technologies, Cantel Medical Corporation Meridian Biosciences, Qiagen GmbH, Nordion, Roche, and Cepheid.